Home  »  Equity Investing   »  Celldex Therapeutics Inc. (CLDX) Announces Success...

Celldex Therapeutics Inc. (CLDX) Announces Successful Results of Phase 1b Skin-Disorder Drug

Celldex Therapeutics Inc. (NASDAQ: CLDX) announced the results of a clinical trial of its drug that is intended to treat dermatological conditions.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


This week, Celldex Therapeutics released new data from a Phase Ib clinical trial of CDX-0159, which targets two dermatological disorders called urticaria. CDX-0159 has shown complete response to therapy in 18 out of 19 patients who received an initial full dose, the company reported.


A patient in the group had a “pronounced partial response”. The trials have shown that patients with cold urticaria (a reaction to cold temperatures) experience a response time of 77 days or more. It was found that patients who presented with symptomatic dermographism (urticaria triggered by light skin scratching) had an average response time of 57 days or more.

The company also reported that CDX-0159 was well tolerated by patients enrolled in the study. However, more clinical trials will be necessary to provide complete safety and efficacy data. The data that are already available have been positively assessed by experts. Especially the German clinic Charite – University of Medicine described the results of CDX-0159 as “overwhelming” at an early stage, representing “a major breakthrough for patients with severe urticaria” for whom modern treatments are ineffective.

Celldex Therapeutics is planning to add new clinical trials to its candidate this year and is examining its efficacy for prurigo nodosum (chronic inflammatory skin disease).

Celldex Therapeutics Inc. (CLDX) share price closed at $44.60, with a gain of 9.66% on July 13. The market capitalization of the company reached $1.69 billion.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts